Bio-Techne Corporation (TECH) has a MoatMap StockRank of 69/100 based on Quality (69/100), Value (25/100), and Momentum (57/100) factor scores. The current signal is BUY. Bio-Techne is the ultimate asset-light, high-margin 'picks and shovels' play for the biologics and cell/gene therapy revolution. With gross margins exceeding 70% and an un-copyable moat in specialized proteins and reagents, it acts as an indispensable gatekeeper. As CDMOs and biopharma firms scale up to meet advanced therapeutic demands, Bio-Techne's validated reagents are locked into clinical protocols, creating high switching costs and recurring revenue.
Bio-Techne Corporation provides high-quality purified proteins, antibodies, immunoassays, and instrumentation essential for life science research and clinical diagnostics worldwide. The company's competitive moat is built on its deep scientific expertise and comprehensive portfolio of specialized reagents and instruments, fostering high customer loyalty among researchers and pharmaceutical firms. Bio-Techne is a key enabling partner in drug discovery, diagnostics, and cell & gene therapy development.
| Price | $53.18 |
| Market Cap | $8.0B |
| P/E (TTM) | 75.97 |
| P/E (Forward) | 25.79 |
| Price/Book | 4.12 |
| Return on Equity | 5.3% |
| Return on Invested Capital | 4.5% |
| Debt/Equity | 13.92 |
| Gross Margin | 66.4% |
| Operating Margin | 25.2% |
| Revenue Growth | -1.5% |
| Dividend Yield | 0.6% |
| Free Cash Flow | $300M |
Bio-Techne Corporation operates in the Biotechnology industry, part of the Healthcare sector (United States).